Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30346095 | 1.00 | KDM1A (0.52) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL30346003 | 0.86 | KDM1A (0.59) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL1985926 | 0.86 | KDM1A (0.59) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL26090253 | 0.86 | KDM1A (0.59) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL7004085 | 0.84 | KDM1A (0.50) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL8016162 | 0.84 | NOTUM (0.63) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL14222127 | 0.83 | KDM1A (0.46) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL21209965 | 0.82 | KDM1A (0.46) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL30027630 | 0.82 | KDM1A (0.46) | KDM1ABCHENOTUMHDAC1HDAC6 | |
| SCHEMBL8562821 | 0.82 | NOTUM (0.46) | KDM1ABCHENOTUMHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118891261-A | Covalent EGFR inhibitors and methods of use thereof | 丹娜-法伯癌症研究院 | 2024-11-01 | — | — | CN | disclosed |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-1948639-A2 | NOVEL CARBOCYCLIC FUSED CYCLIC AMINES | F. Hoffmann-la Roche AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054453-A2 | CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | KDM1A 1598/4885BCHE 420/4885NOTUM 1722/4885 |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | KDM1A 2409/4885BCHE 3156/4885NOTUM 3686/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | KDM1A 1598/4885BCHE 420/4885NOTUM 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.